Hot Life Science Investor Mandate 3: Large Pharma Group Seeking Investment, In-Listening and M&A Opportunities in a Number of Indications

13 Aug

A large pharma group based in the US is looking to form partnerships with development stage biotech companies via a variety of structures, including strategic venture investments, in-licensing, collaborations, and M&A. The firm is actively pursuing these opportunities and is willing to look globally.

The firm focuses on therapeutic assets in oncology (including immuno-oncology), immunology, and neurodegenerative diseases.  The firm is also interested in fibrotic diseases of the liver (such as HBV). The firm is open to both biologic and small molecule opportunities, but is generally not focused on cell therapies such as CAR-T technologies. The firm will consider assets at any stage of development, but is particularly interested in outreach from companies developing early stage technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: